Background and Purpose-The effects of anticoagulation therapy and elevated international normalized ratio (INR) 
B
ecause of the increasing age of the general population and significant improvements in imaging techniques, the number of patients with unruptured and often incidental intracranial aneurysms is increasing. 1 Management of these patients is controversial and one of the major challenges facing neurosurgeons today because the case fatality rate of aneurysmal subarachnoid hemorrhage (aSAH) remains high. [1] [2] [3] [4] Although prevention of rupture with surgical or endovascular treatment is considered to be the most effective approach, treatment-related risks and complications remain a significant problem. 1 To make a calculated assessment about the lifetime risk of rupture compared with the risk of treatment, it is of paramount importance to understand the natural history of unruptured intracranial aneurysms and its related risk factors. Although several aneurysm and patient-related risk factors for aSAH have been identified, such as hypertension and smoking, the natural history of unruptured intracranial aneurysms has yet to be clearly defined. [5] [6] [7] [8] As the use of anticoagulation therapy for atrial fibrillation, mechanical heart valves, and other indications is rapidly increasing with an aging population, neurosurgeons should be aware of the concomitant risks of this treatment. Recent population-based studies have reported contradictory findings about the association between anticoagulant therapy and SAH risk. [9] [10] [11] [12] However, these reports did not include or specify the number of aSAH and were limited because of a low number of patients on anticoagulant therapy, 12 lack of inclusion of important confounding factors, such as smoking and alcohol use, 9 the use of standardized diagnosis codes with possible misclassification and lower diagnostic validity as a
Elevated International Normalized Ratio Is Associated
With Ruptured Aneurysms 10 Given the widespread use of anticoagulant therapy and the potential fatal consequences of aSAH, we conducted a large casecontrol study investigating the magnitude and direction of the association between anticoagulation use, INR values, and the risk of aSAH.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request. The medical records of 4696 patients who were diagnosed with an intracranial aneurysm between 1990 and 2016 at the Brigham and Women's Hospital and Massachusetts General Hospital and who were either on no anticoagulant therapy or on warfarin at the time of diagnosis were reviewed. This study has been approved by our institutional review board and considered minimal risk. Patient consent was, therefore, waived by the board. Patients were identified prospectively on clinical presentation (2007-2016) and retrospectively using natural language processing in conjunction with the Partners Healthcare Research Patients Data Registry, which includes 4.2 million patients who have received care from Brigham and Women's Hospital and Massachusetts General Hospital (1990 Hospital ( -2013 . 13 International Classification of Diseases Ninth Revision (ICD-9) and Current Procedural Terminology (CPT) codes were used to obtain an initial set of potential aneurysm patients from the Research Patients Data Registry, and natural language processing was then used together with codified features to train a classification algorithm which classified 5589 patients as having aneurysm with a positive predictive value of 0.91. Of the 5589 patients, 727
were also seen on clinical presentation from 2007 to 2013 with prospectively collected data. Four hundred and seventy-four additional patients who were seen on clinical presentation from 2013 to 2016 were included with prospectively collected data. The medical records and imaging studies of the 6063 patients were reviewed in detail (Drs Can and Du) to identify 4696 patients with definite saccular aneurysms and who were on no anticoagulant therapy or on warfarin. Patients on low-molecular weight heparin were excluded. Of the 4696 patients, 1198 were obtained prospectively. The results of the imaging studies, including intracranial aneurysm site and size, were recorded. Patients with possible infundibula or nondefinitive diagnoses of aneurysms, feeding artery aneurysms associated with arteriovenous malformations, fusiform, or dissecting aneurysms, and those lacking clinical notes or radiographic images were excluded from the present study. In addition, patients who received treatment of their aneurysm(s) before presentation were also excluded from the present study. Patients who presented with an aSAH were categorized as harboring a ruptured aneurysm.
Patient demographics (age, sex, and race), comorbidities (hypertension, coronary artery disease, myocardial infarction, and atrial fibrillation), number and maximum size of intracranial aneurysms, family history of aneurysms or family history of SAH, and current tobacco and alcohol use were obtained. The diagnosis of aSAH was confirmed with a computed tomographic scan, cerebrospinal fluid analysis, or intraoperatively by a neurosurgeon. In addition, we collected detailed data about anticoagulant use, type of anticoagulant, indication, and INR values at the time of diagnosis of the intracranial aneurysms. A risk factor was assumed to be absent if we found no documentation of its presence. INR values were obtained at the time of diagnosis for ruptured aneurysms and within a year of diagnosis for unruptured aneurysms. For patients whose initial INR at the time of diagnosis were obtained while heparinized and falsely elevated, the next available INR after the partial thromboplastin time had normalized was used. Patients were classified as anticoagulant users if they To control for differences in baseline characteristics, inverse probability weighting using propensity scores was applied. Covariate balance was tested after inverse probability weighting using a χ 2 test.
Missing values were accounted for by using multiple imputation with chained equations, and inferential statistics were obtained from 40 imputed datasets. Sensitivity analyses using subgroups consisting of complete cases (ie, without missing data) only, anticoagulation users only, and nonanticoagulation users only were also performed. All statistical analyses were performed using the Stata statistical software package (version 14, StataCorp College Station, TX).
Results
Summary statistics of patient demographics and characteristics stratified by anticoagulant use are shown in Table 1 . A total of 4696 patients with 6403 aneurysms were included, of which 1300 (27.7%) patients presented with a ruptured aneurysm. In general, patients on anticoagulant therapy were significantly older, less frequently current smokers, and more frequently diagnosed with hypertension, coronary artery disease, myocardial infarction, and atrial fibrillation. In addition, INR values were significantly higher in anticoagulated patients.
Covariance balance was optimized with inverse probability weighting using propensity scores. The results of the unweighted and weighted multivariable analyses are shown in Table 2 . Five out of 10 variables had a standardized mean difference of 10% or higher, indicating possible confounding before inverse probability weighting. This number decreased to 2 after weighting (Table 3 ). In the weighted multivariable analysis, current alcohol use (OR, 1.89; 95% CI, 1.10-3.24) To examine the effects of this interaction for specific INRs, the marginal effect was calculated. We found that in anticoagulant users, the marginal effects of anticoagulant therapy on rupture risk were negative and significant for INR 1.2 and higher (Figure 1 ). Although the size of some coefficients changed slightly, the direction and significance of most coefficients remained the same in the sensitivity analysis using complete cases only, with the exception of tobacco use which became significant and alcohol use which lost significance (Table I in the online-only Data Supplement). In the subgroup analysis of patients not on anticoagulation, INR values were also associated with a higher risk of rupture at presentation (Table II in the online-only Data Supplement). The cause for elevated INR in nonanticoagulated patients included liver disease, bleeding disorder, and vitamin K deficiency (Table III in the online-only Data Supplement). In the subgroup analysis of anticoagulated patients, there was a similar trend for INR although it did not reach statistical significance (Table II in the online-only Data Supplement). Figure 2 shows the proportion of ruptured aneurysms stratified according to INR values among anticoagulant users and nonusers. The ORs and significance levels for INR in the weighted models were similar to the unweighted models ( Table 2 ; Table I in the online-only Data Supplement).
Discussion
We evaluated whether anticoagulation therapy and elevated INR values in patients with intracranial aneurysms were associated with rupture. Our primary finding is that elevated INR is significantly associated with ruptured aneurysms, even when adjusted for a wide variety of confounders. Interestingly, the effects of INR seem to be ameliorated by anticoagulant use at INR levels of 1.2 and higher. Whether the use of anticoagulants influences the risk of SAH has been the focus of a limited number of population-based 
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studies with inconsistent results. [9] [10] [11] [12] 14, 15 In a registry-based Danish study using prescription data, a significant association between anticoagulation therapy and SAH could not be found. 12 However, only 9 patients with SAH were current users of vitamin K antagonists, important confounders such as smoking and alcohol use were lacking, and inclusion of patients based on diagnosis codes could have led to misclassification of SAH cases. In contrast, in a subsequent Dutch population-based study, vitamin K antagonists were significantly associated with SAH (OR, 2.46; 95% CI, 1.04-5.82). 11 The most recent population-based study on this topic showed no association between anticoagulant use and SAH (<1 month: OR, 1.85; 95% CI, 0.97-3.51 and >3 years: OR, 1.24, 95% CI, 0.86-1.77). 9 However, in all 3 studies, INR values were not available, preventing the authors from drawing firm conclusions on coagulation status and the risk of aSAH because noncompliance in anticoagulant users could bias the results. García-Rodríguez et al 10 Moreover, their control group consisted of subjects with an unknown incidence of unruptured aneurysms, in contrast to our study. One of the major limitations of all previously mentioned population-based registries are misclassification bias and information bias, both on the level of outcome and exposure, because of the use of diagnosis codes and subsequent decreased accuracy in diagnosis. 11 Previous studies reported an increased risk of intracerebral hemorrhage in anticoagulant users. 16 In addition, intracerebral hemorrhage associated with oral anticoagulant use was highly associated with mortality risk because of early hematoma growth. 17, 18 In contrast, we recently showed in a nationwide study that anticoagulant use was not associated with differential mortality or complication rates after aSAH. 19 Our current results indicate that anticoagulants, by decreasing the effects of increased INR values, may be protective against intracranial aneurysm rupture at a given INR value. This protective effect could be because of additional pharmacodynamic characteristics of oral anticoagulants beyond the inhibition of vitamin K-dependent coagulation factors, such as possible immunomodulatory properties. 20 Indeed, it has been shown that anticoagulation with warfarin downregulates inflammation by inhibition of IL-6 (interleukin-6) production and TNF (tumor necrosis factor)-induced I-κβ phosphorylation and consequent inflammatory signal transduction. 21, 22 Because vascular inflammation, specifically TNF-mediated inflammation, is thought to play a key role in intracranial aneurysm pathogenesis, 23, 24 the anti-inflammatory effects of warfarin may provide the explanation for its ameliorating effects on INR elevation and subsequent aneurysm rupture, as shown in our study. However, it is also possible that the patients with elevated INR but who were not anticoagulated may have involvement of other parts of the coagulation pathway beyond what is detectable by INR and be more susceptible to aneurysm rupture as a result. 25 The main strengths of our study are the large sample size, the presence of a large control group with unruptured intracranial aneurysms, and the use of a high-quality, homogeneous database, including INR values for anticoagulant users and nonusers. The main limitation of our study includes the retrospective design for a portion of the patients. It is possible that the decreased association between the effects of INR in anticoagulated patients and aneurysm rupture is noncausal but because of the increased use of intracranial imaging in anticoagulated patients leading to the increased discovery of unruptured aneurysms. However, propensity score weighting was used to control for selection bias. The subgroup analysis of anticoagulated patients showed a trend in the association of elevated INR with aneurysm rupture. The lack of statistical significance may be because of insufficient power because of the small sample size of that subgroup.
With an increasing number of unruptured intracranial aneurysms being diagnosed every year, specifically in an older population with poly-pharmacy and comorbidities, such as atrial fibrillation and valvular diseases, the present study addresses a clinically relevant question for the clinician. In deciding on the optimal management of unruptured intracranial aneurysms in patients with elevated INR values, the treating physician must understand the effect of anticoagulation therapy and elevated INR values on the natural history of unruptured intracranial aneurysms. Our results advocate caution with anticoagulant prescriptions in this vulnerable but growing patient population.
Summary
In conclusion, we found that elevated INR values are significantly associated with an increased risk of aSAH in patients with unruptured intracranial aneurysms and that the effects may be moderated by anticoagulation therapy. Future randomized control trials are needed to confirm these findings. 
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